News | January 28, 2008

Endovascular Graft Appears Safer than Thoracotomy

January 28, 2008 - A new multi-center, international clinical trial that compares the safety and effectiveness of thoracic endovascular aortic repair (TEVAR) to open surgery for descending thoracic aortic aneurysms (TAA), indicates that TEVAR (the less invasive endovascular graft) is a promising treatment option for many patients.

Jon S. Matsumura, M.D., vascular surgeon at Northwestern Memorial Hospital and associate professor of surgery of Northwestern University Feinberg School of Medicine, has found that the one year survival estimates are 91.6 percent for patients in the endovascular group compared to 85.5 percent in the thoracotomy group. There were no aneurysm ruptures in either group in the first year. The results of this trial were published in the February issue of the Journal of Vascular Surgery.

Dr. Matsumura and co-authors Richard P. Cambria, M.D., Michael D. Dake, M.D., Randy D. Moore, M.D., Lars G. Svensson, M.D., and Scott Snyder PhD analyzed 12-month data on 230 patients treated at 42 hospitals in America, Australia, Canada, Poland, Czech Republic and Italy. When comparing the 160 patients treated with TEVAR to the 70 patients treated with thoracotomy repair they found TEVAR has:
• shorter procedure times
• fewer transfusions
• fewer intensive care days
• less than half the risk of major complications
• less than a third the risk of severe complications, including less than a third the risk of stroke and less than a fourth the risk of permanent paralysis
• shorter recovery times

This trial evaluated the Zenith TX2 TAA Endovascular Graft. This mature endovascular graft is made with surgical graft material sutured to self-expanding stainless steel stents and is precisely deployed with an advanced catheter system inserted through a small incision in the patient's groin artery. The device is investigational and is undergoing thorough review of the data by federal regulators.

Our results demonstrate that endovascular repair has striking potential benefits for patients with TAA," said Dr. Matsumura. "These patients need long-term follow-up to evaluate the durability of this new minimally invasive alternative to thoracotomy repair."

Thoracic aortic aneurysms affect approximately six of every 100,000 persons. The risk of rupture for large aneurysms is approximately 74 percent in patients without repair and more than 90 percent of those patients do not survive a rupture, according to one population-based study. Conventional treatment is a major operation involving thoracotomy (opening of the chest cavity through the ribs), sutured replacement of the diseased aorta with a fabric tube graft, and often requires partial heart bypass. Major complications include bleeding, stroke and paralysis of the lower half of the body.

Journal of Vascular Surgery provides vascular, cardiothoracic, and general surgeons with the most recent information in vascular surgery. Original, peer-reviewed articles cover clinical and experimental studies, noninvasive diagnostic techniques, processes and vascular substitutes, microvascular surgical techniques, angiography and endovascular management. Special issues publish papers presented at the annual meeting of the Journal's sponsoring society, the Society for Vascular Surgery.

For more information:

Related Content

SherpaPak Cardiac Transport System Cleared for Pediatric and Small Donor Hearts
Technology | Cardiovascular Surgery | February 01, 2019
Paragonix Technologies Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) for a design...
Transplanting Pig Hearts Into Humans One Step Closer. A pig heart, shown here, is very similar in size and anatomy to a human heart. For this reason, pigs are used extensively in pre-clinical animal testing for new implantable cardiovascular devices. If pig hearts could be used for human transplantation, it would greatly alleviate shortages of donor human hearts.

A pig heart, shown here, is very similar in size and anatomy to a human heart. For this reason, pigs are used extensively in pre-clinical animal testing for new implantable cardiovascular devices. If pig hearts could be used for human transplantation, it would greatly alleviate shortages of donor human hearts.

News | Cardiovascular Surgery | December 11, 2018
The scientific journal Nature recently published an article from Munich University Hospital which describes the long-...
Bilateral Artery Use Does Not Improve 10-Year CABG Outcomes
News | Cardiovascular Surgery | September 06, 2018
While it is firmly established that the use of one internal thoracic artery can improve life expectancy in coronary...
Mandatory Public Coronary Artery Bypass Grafting Reporting Associated With Better Patient Outcomes
News | Cardiovascular Surgery | April 30, 2018
Mandatory public reporting of coronary artery bypass grafting (CABG) results in Massachusetts was associated with...
Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery | September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
ClearFlow Inc. Announces Positive U.S. Clinical Trial Results
News | Cardiovascular Surgery | September 08, 2017
September 8, 2017 — ClearFlow Inc.
Videos | Cardiovascular Surgery | July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Intensive Glycemic Control Program Produces Significant Per-Patient Cost Savings for CABG Surgery
News | Cardiovascular Surgery | May 25, 2017
A new study from Emory University observed a near-20 percent reduction in perioperative complications, a 1.2-day...
Risk of Heart Transplant Rejection Reduced by Desensitizing Patient Antibodies
News | Cardiovascular Surgery | May 23, 2017
The risk of heart transplant rejection can be reduced by desensitizing patient antibodies, according to research...
Overlay Init